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OBJECTIVES: This is a retrospective cohort study examining the development of
prolonged neutropenia as a result of the induction chemotherapy R-CHOP/CHOP in
diffuse large B-cell lymphoma (DLBCL) patients. It aims to 1) identify the incidence
and predictive factors of the prolonged neutropenia, and 2) evaluate the infection
complications and clinical outcomes of prolonged neutropenia in this patient
group. METHODS: Medical records of 43 DLBCL patients who received R-CHOP/
CHOP induction treatment between the year 2000 and 2010 at Prince of Wales
Hospital (PWH) were reviewed. Information including basic demographic informa-
tion, disease-related characteristics, and laboratory values were recorded. Inci-
dence of prolonged neutropenia, duration of neutropenic episodes, and infection
complication and outcomes were also collected. Correlations between possible
predictive/risk factors and the occurance of prolonged neutropenia were examined
using univariate analysis and multivariate logistic regression analysis. RESULTS:
Inpatient status (OR: 12.000, p-value  0.006), Ann Arbor stage III or IV (OR: 3.886,
p-value 0.049) and International Prognostic Index (IPI) high risk group (OR: 5.257,
p-value  0.020) were identified as predictive factors of prolonged neutropenia.
Prolonged neutropenia has been shown to cause significant longer duration of
hospitalization, increased ICU admission, dose reduction and delay in chemother-
apy or even early termination of treatment. The use of prophylactic G-CSF and/or
antibiotics has also been shown to reduce the occurrence of prolonged
neutropenia. CONCLUSIONS: Several predictive factors were demonstrated to
have association with the occurrence of prolonged neutropenia in DLBCL patients
after receiving R-CHOP/CHOP. Preventive measures, including prophylactic G-CSF
and/or antibiotics, should be considered as part of the treatment for the patients at
risk.
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OBJECTIVES: The monoclonal antibodies (mAbs) bevacizumab (Bmab), cetuximab
(Cmab), and panitumumab (Pmab) have been indicated for the treatment of pa-
tients with metastatic colorectal cancer (mCRC). The objective of this study was to
describe the incidence of adverse events (AEs) among patients with mCRC treated
in clinical practice. METHODS: Medical chart review was conducted for patients
treated at three US cancer centers from January 2004 to March 2009. Qualifying
cases were adults with: a diagnosis of colorectal cancer AND evidence of metastasis
AND receiving mAb therapy. AEs that were listed in mAb package inserts were
examined in the medical records. Grade 3/4 AEs occurring during mAb treatment
that were due to or possibly due to the mAb were identified. The Incidence of AEs
is reported across all patients and with each specific mAb. RESULTS: Among 103
patients with mCRC, 54 experienced 139 AEs that met study criteria. The overall
study sample was predominately Caucasian (99%), average age 57.6 years, 51.5%
female, and located in the Northeast (28.2%) and Midwest (70.9%). The majority of
patients (87%) were on chemotherapy. Grade 3/4 AEs that occurred with a fre-
quency 5% were: rash (24%) (Bmab 11%, Cmab 33%, Pmab 25%), diarrhea (18%)
(Bmab 14%, Cmab 17%, Pmab 15%), neutropenia (15%) (11% for Bmab and Cmab, 0%
for Pmab), vomiting/nausea (9%) (Bmab 5%, Cmab 7%, Pmab 5%), infusion reaction
(8%) (Bmab 3%, Cmab 13%, Pmab 0%), and venous thrombosis (7%) (8% for Bmab, 0%
for Cmab and Pmab). CONCLUSIONS: In this study of patients treated in commu-
nity practices, the incidences of AEs with mAb therapies in patients with mCRC had
similar patterns as those reported in the individual FDA labels. The findings could
be confounded by differences in time on therapy among mAbs. Additional research
with larger sample sizes is needed to more thoroughly examine these AEs in clin-
ical practice.
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OBJECTIVES: Currently, data regarding the prevalence of cardiovascular comor-
bidities in patients with metastatic colorectal cancer (mCRC) are limited. This
study determined the rate of comorbid cardiovascular diseases in patients with
mCRC, as comorbidities may impact treatment decisions, prognoses, and quality of
care.METHODS: From the PHARMO Record Linkage System (RLS), including among
other things, drug dispensing and hospitalization records of approximately 3.2
million residents in the The Netherlands, all patients with a primary or secondary
hospital discharge code for CRC and distant metastasis between 2000 and 2008
were selected and defined as patients with mCRC. The first discharge diagnosis
defining metastases served as the index date. Prevalent cardiovascular comorbidi-
ties were assessed during the 12 months prior to the index date and patients were
required to be registered in the PHARMO RLS during this period to be included in
the study cohort. Cardiovascular comorbidities were captured using both cardio-
vascular drug use and hospital admission data. RESULTS: A total of 2,964 patients
with mCRC were included in the analysis. Mean ( standard deviation) age at
diagnosis was 68 ( 12) years and 53% were male. Overall, cardiovascular comor-
bidities were observed in 52% of the patients. Of all patients identified by drug use
(n1,479), the most commonly used agents were antithrombotic agents (54%), fol-
lowed by beta blocking agents (46%), and agents acting on the renin-angiotensin
system (45%). Of the patients who were hospitalized for cardiovascular comorbidi-
ties during the year prior to index date (n297), about one-third was hospitalized
for cardiac dysrhythmia (39%), followed by congestive heart failure (19%) and hy-
pertension (18%). CONCLUSIONS: Cardiovascular comorbidities are commonly
seen in patients with mCRC, which might be explained by the high mean age at
diagnosis. Consideration of these conditions should be an integral part of the treat-
ment strategy in individual patients with mCRC.
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OBJECTIVES: To assess the efficacy of bevacizumab plus chemotherapy compared
with chemotherapy alone in previously untreated metastatic colorectal cancer
(mCRC) patients, who are appropriated for intensive therapy.METHODS:A system-
atic review of the literature was conducted. The selection criteria of the studies for
this review were: health technology agencies reports, meta-analysis, systematic
reviews and randomized controlled trials (RCTs), in mCRC comparing chemother-
apy plus bevacizumab with chemotherapy alone. Searches were realized in MED-
LINE, EMBASE, the Cochrane Library, and CRD databases until the 8th of June 2011.
The end points evaluated were overall survival (OS), progression-free survival
(PFS), overall tumour response rate (RR), and quality of life (HRQoL). The selection of
the studies, quality assessment, data extraction and data analysis were done in-
dependently by two authors. Disagreements were resolved by a third reviewer until
consensus was obtained. RESULTS: Two RCTs comparing chemotherapy plus be-
vacizumab with chemotherapy alone for first-line treatment of mCRC were in-
cluded in the efficacy assessment. The chemotherapy in one of these trials was the
IFL regimen and in the other trial was XELOX/FOLFOX-4. The addition of bevaci-
zumab to IFL showed an increase in terms of OS (Hazard Ratio (HR): 0.66, p0.001),
PFS [HR: 0.54, p0.001], and RR. IFL is not current standard chemotherapy and it is
not an adequate comparator. The addition of bevacizumab to XELOX/FOLFOX-4
resulted in statistically significant difference in terms of PFS (HR: 0.83; Confidence
Interval 97.5%: 0.72-0.95). The median OS was not statistically significant, and the
RR was similar in both arms. No RCTs comparing bevacizumab with FOLFIRI vs.
FOLFIRI were found. None of the studies reported the impact of bevacizumab treat-
ment on HRQoL. CONCLUSIONS: The combination of bevacizumab with chemo-
therapy increases PFS in untreated mCRC, in patients who tolerate intensive ther-
apy. The improvement in terms of OS remains uncertain. OBJECTIVES: To assess
the efficacy of bevacizumab plus chemotherapy compared with chemotherapy
alone in previously untreated metastatic colorectal cancer (mCRC) patients, who
are appropriated for intensive therapy. METHODS: A systematic review of the lit-
erature was conducted. The selection criteria of the studies for this review were:
health technology agencies reports, meta-analysis, systematic reviews and ran-
domized controlled trials (RCTs), in mCRC comparing chemotherapy plus bevaci-
zumab with chemotherapy alone. Searches were realized in MEDLINE, EMBASE, the
Cochrane Library, and CRD databases until the 8th of June 2011. The end points
evaluated were overall survival (OS), progression-free survival (PFS), overall tu-
mour response rate (RR), and quality of life (HRQoL). The selection of the studies,
quality assessment, data extraction and data analysis were done independently by
two authors. Disagreements were resolved by a third reviewer until consensus was
obtained. RESULTS: Two RCTs comparing chemotherapy plus bevacizumab with
chemotherapy alone for first-line treatment of mCRC were included in the efficacy
assessment. The chemotherapy in one of these trials was the IFL regimen and in
the other trial was XELOX/FOLFOX-4. The addition of bevacizumab to IFL showed
an increase in terms of OS (Hazard Ratio (HR): 0.66, p0.001), PFS [HR: 0.54,
p0.001], and RR. IFL is not current standard chemotherapy and it is not an ade-
quate comparator. The addition of bevacizumab to XELOX/FOLFOX-4 resulted in
statistically significant difference in terms of PFS (HR: 0.83; Confidence Interval
97.5%: 0.72-0.95). The median OS was not statistically significant, and the RR was
similar in both arms. No RCTs comparing bevacizumab with FOLFIRI vs. FOLFIRI
were found. None of the studies reported the impact of bevacizumab treatment on
HRQoL. CONCLUSIONS: The combination of bevacizumab with chemotherapy in-
creases PFS in untreated mCRC, in patients who tolerate intensive therapy. The
improvement in terms of OS remains uncertain.
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OBJECTIVES: Chronic myeloid leukemia (CML) is a progressive disease consisting
of three phases: chronic, accelerated and blast crisis. Imatinib achieves high re-
sponse rates and improves prognosis. Dasatinib is a BCR-ABL kinase inhibitor ap-
proved for treating CML across all phases of disease. The present study modeled
the time to response, time to accelerated phase, blast crisis and death of newly
diagnosed patients with CML receiving first line therapy with dasatinib 100 mg/day
or imatinib 400 mg/day in the chronic phase. METHODS: A Markov simulation
model was developed using two cohorts of 200,000 CML patients treated with da-
satinib 100 mg/day or imatinib 400 mg/day. Health states included were complete
cytogenetic response (CCyR), major cytogenetic response (MCyR), no-response,
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transformation to accelerated phase or blast crisis and death. A 5-year time hori-
zon was considered. Each 3 months the patient faces a probability of staying in the
same health state or moving to a next state. Transition to death is possible from all
health states. This model was populated with efficacy data from clinical trials and
different times to events were modeled using Weibull regression techniques.
RESULTS: The Weibull model for the time to response and time to transformation
to accelerated phase and blast crisis showed significant differences between treat-
ment groups. The model coefficient indicated that the chance of response was
higher in dasatinib patients with a difference of 12.54% versus imatinib. Patients
receiving imatinib had 1.57% higher chance of moving to the accelerated phase and
blast crisis earlier. Time to death did not differ significantly between treatments.
CONCLUSIONS: The analysis showed earlier responses and a lower chance of
reaching the accelerated phase and blast crisis faster with dasatinib 100 mg/day
over imatinib 400 mg/day. Results were obtained according to the assumptions
used but will need to be validated by future patient level data.
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OBJECTIVES: The treatment of patients with Multiple Myeloma (MM) has changed
significantly over the last years. The clinical registry on Multiple Myeloma (TLN
Registry) conducted by the iOMEDICO AG in collaboration with the Arbeitskreis
Klinische Studien (AKS) and the Kompetenznetz Maligne Lymphome was estab-
lished to follow the implementation of new standards into daily practice. Here, we
present data regarding the therapy reality of MM patients treated by office-based
oncologists in Germany. METHODS: With a target population of 500 MM patients,
the registry prospectively collects data on the treatment of MM patients, including
patient characteristics. In addition, data on tumour history, response rates, ad-
verse drug reactions and concomitant diseases are documented. MM patients older
than 18 years receiving a 1st- or 2nd-line therapy which has started no longer than
4 weeks before patient enrolment can be recruited into the registry if informed
written consent is present. Currently, 114 sites in Germany are participating.
RESULTS: The registry started in May 2009. By February 2011, 353 patients with MM
have been enrolled. Mean age of MM registry population is 70 years at the onset of
the systemic 1st-line therapy. Bortezomib/Melphalan/Prednisone is most often
used as 1st-line treatment (28%), whereas the Bortezomib/Dexamethasone combi-
nation (16%), the Lenalidomide/Dexamethasone combination (14%) or the Bort-
ezomib monotherapy (13%) is most often used as 2nd-line treatment, regardless if
stem cell transplantation was reported. On average, MM patients receiving Bort-
ezomib/Melphalan/Prednisone are older than patients who are treated with Bort-
ezomib/Dexamethasone in both 1st- and 2nd-line treatment. CONCLUSIONS: The
registry provides an overview of the current treatment of patients with MM treated
by office-based oncologists in Germany. Furthermore, the registry shows how fast
research results concerning the treatment of MM patients are transferred into
current medical practice.
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OBJECTIVES: Anti-angiogenic therapy has become an integral component of treat-
ment for metastatic colorectal cancer patients. During last 10 years several studies
were conducted to test the safety and efficacy of anti-angiogenic therapies in mCRC
patients. This study reviewed the results of randomized controlled trials published
in peer-reviewed journals. METHODS: We searched the MEDLINE, and abstracts
from ECCO, ESMO and ASCO until May 2011. Studies were selected for randomized
controlled trials on targeted anti-angiogenic drugs in mCRC. Primary endpoints
reviewed were progression-free (PFS) and overall survival (OS). Response rates,
toxicity and secondary resectability were secondary endpoints. Aggregated data
were further analyzed to understand comparative safety and efficacy. RESULTS:
Until May 2011, eligible mCRC randomized clinical trials for this review were avail-
able for bevacizumab (5 trials including 3101 patients) and vatalanib (2 trial includ-
ing 2033 patients). Overall, anti-angiogensis therapy for mCRC shows significant OS
and PFS benefit versus comparators. The median OS and PFS benefit for regimens
containing Bevacizumab were 3 and 3.15 months, versus background chemother-
apy. The median OS and PFS benefit for vatalanib containing regimens were sta-
tistically insignificant versus background chemotherapy. CONCLUSIONS: Anti-an-
giogensis therapy with Bevacizumab for mCRC shows significant OS and PFS
benefit versus comparators.
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OBJECTIVES: In Hungary annually 35,000 people die because of malignant cancer.
The main characteristics of the treatment of cancer are multidisciplinary and com-
plex approach. The aim of our examination was to measure the effectiveness of
dance rehabilitation group of female patients suffering from malignant tumours,
and the changes of lifestyle and social support of patients. METHODS: Our exam-
ination is descriptive, prospective and quantitative. Female patients suffering from
malignant cancer illnesses were examined with random sampling method be-
tween 2005- 2009. Follow-up was implemented a year later. Data was collected with
standardised (F-SoZu, EORTC-QLQ-C30, Campbell) and own-designed question-
naires. Data of 175 patients were processed. Statistical analysis was made with
SPSS 17. RESULTS: The average age of patients in the dance group was 48.87 years
(SD:8,87) and 51,13 in the control group (SD:11,06). The degree of social support in
the dance group was 65,22 at the first, 67,55 at second time. In case of the control
group the rate was firstly 57,41 then 53,88. The change in the degree of social
support was significant in both groups between the two measures (p0.01). Pa-
tients attending in the dance group had less corporal and psychic symptoms at
both measures than the members of the control group. In case of the questionnaire
of Campbell the scores in the dance group was higher in both measures than in the
control group. The two groups differ in the degree of change: the dance group had
more significant change in case of complacency with life compared to the other
group. CONCLUSIONS: Dance as a rehabilitation method need less investment
form the state and it does not charge the Social Insurance Fund. These arguments
cannot be neglected in the current economic status. Care system would get a re-
habilitation which may help women to return actively to society.
PCN16
DISEASE BURDEN AND TREATMENT OUTCOMES IN SECOND-LINE THERAPY OF
PATIENTS WITH ESTROGEN-RECEPTOR POSITIVE (ER) ADVANCED BREAST
CANCER: A REVIEW OF THE LITERATURE
Boswell KA1, Wang X2, Shah MV1, Aapro MS3
1Xcenda, Palm Harbor, FL, USA, 2Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA,
3Multidisciplinary Oncology Institute, Genolier, Switzerland
OBJECTIVES: To determine the variable burden of disease of patients with ad-
vanced ER breast cancer and assess the current treatment landscape after failure
of ER first-line therapy. METHODS: A comprehensive literature review was per-
formed (2000–2011) by searching Medline via PubMed and Embase and Cochrane
databases to assess disease burden (ie, societal, humanistic and/or economic bur-
den) and treatment landscape for second-line therapy of ER advanced breast
cancer in postmenopausal women. RESULTS: Only 1 study was identified that
evaluated burden of disease based on ER status (ER, ER-, or ER-unknown), which
was a subgroup analysis assessing the impact of recurrence over 10 years. The
investigators reported that only minor differences in survival and medical costs
were noted according to ER status. Regardless of ER status, patients with breast
cancer recurrence consumed more health care resources and were associated with
more costly care than those without recurrence. A total of 7 studies were identified
related to treatment outcomes of ER second-line therapy. A combined interna-
tional population totaled 3,800 patients who had progressed on prior hormonal
therapy, including tamoxifen and aromatase inhibitors. Three trials performed a
comparative efficacy/safety assessment of ER antagonist vs aromatase inhibitor
and 1 trial each for aromatase inhibitor versus megestrol acetate and aromatase
inhibitor versus aromatase inhibitor. Among each of the studies evaluated, no
significant differences were observed in the primary efficacy endpoint, and the
safety profiles were similar. Two additional studies, both dosing evaluations, dem-
onstrated that lower doses had a similar or better efficacy and safety profile.
CONCLUSIONS: Currently, there is insufficient evidence on the economic and hu-
manistic burden associated with ER status, and this gap warrants further research.
With increasing drug resistance and greater economic burden associated with
breast cancer recurrence, there is an unmet medical need for improved treatment
in this patient population.
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OBJECTIVES:To determine whether surrogate end points [progression free survival
(PFS), time to progression (TTP) and response rate (RR)] are correlated with overall
survival (OS) in the first-line treatment of advanced or metastatic breast cancer
(BC). METHODS: A systematic review of the literature was conducted to indentify
randomized clinical trials (RCTs) that evaluate the efficacy of chemotherapy in
first-line treatment of advanced or metastatic BC. Searches were realized in MED-
LINE and EMBASE databases from 1995 to April 2010. The nonparametric Spearman
rank correlation coefficient (rs) was used as a measure of correlation between the
difference (	) in surrogate outcomes (	PFS, 	TTP and 	RR) and the difference in OS
(	OS). Correlation coefficients were compared using the normal approximation to
the z-transformation of rs and its standard deviation. Linear regression analysis,
through the origin of the plot, evaluating 	OS as a function of differences in each
surrogate outcomes was used to determine the proportion of variability explained
(R2). Statistical analyses were performed using STATA software v.10. RESULTS:
Thirty-four RCTs were included in the analysis, with a total of 11,398 patients
evaluated. In the first-line therapy of advanced or metastatic BC, there was a weak
significant association between 	PFS and 	OS [rs: 0.43 (Confidence Interval (CI)
95%: 0.04-0.71)]. When the analysis was performed including only RCTs in the
metastatic stage, the rs data between 	PFS and 	OS increased statistically signifi-
cant to 0.59 (CI95% 0.17 to 0.83). The surrogate outcomes that correlated better with
the 	OS, were 	TTP [rs: 0,79 (CI95%: 0,43-0,94); R2:62%], and 	RR [rs: 0,73 (CI95%:
0,55-0,85); R2: 53%]. CONCLUSIONS: In the first-line treatment of advanced or met-
astatic BC, TTP and RR may be appropriate surrogate end points for OS, although it
is important to consider the magnitude of their variations.
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